The immunological basis for treatment of multiple sclerosis

Scandinavian Journal of Immunology

Volumn 66, Issue 4, 2007, Pages 374-382

  Holmoy T ^a   Vartdal, F ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALPHA B CRYSTALLIN; AUTOANTIGEN; BETA1A INTERFERON; CLADRIBINE; CRYSTALLIN; CYCLOPHOSPHAMIDE; DACLIZUMAB; FINGOLIMOD; GLATIRAMER; GLOBULIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN G; INTERFERON BETA SERINE; LAMOTRIGINE; MBP 8298; MEMANTINE; MITOXANTRONE; MYELIN BASIC PROTEIN; MYELIN PROTEIN; NATALIZUMAB; OLIGOCLONAL BAND; PIOGLITAZONE; PROTEOLIPID PROTEIN; RITUXIMAB; T LYMPHOCYTE ANTIGEN; UNCLASSIFIED DRUG; VITAMIN D;

ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; BLOOD BRAIN BARRIER; CLINICAL TRIAL; ENVIRONMENTAL FACTOR; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL MONITORING; IMMUNOLOGICAL PROCEDURES; IMMUNOTHERAPY; INFLAMMATION; LYMPHOCYTE MIGRATION; MEDICAL LITERATURE; MESENCHYME CELL; MULTIPLE SCLEROSIS; NERVE DEGENERATION; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TARGET CELL; VISUAL HALLUCINATION;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HERPESVIRUS 4, HUMAN; HISTOCOMPATIBILITY ANTIGENS; HUMANS; IMMUNOTHERAPY; MULTIPLE SCLEROSIS; RECEPTORS, ANTIGEN, T-CELL; VITAMIN D DEFICIENCY;

EID: 34548545064     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2007.01982.x     Document Type: Review

References (100)

1. Kabat E. An elctrophoretic study of the protein components in cerebrospinal fluid and their relationship to serum proteins. J Clin Invest 1942 21 : 571 7.
2. Koritschoner RS, Schweinburg F. Induktion von Paralyse und Rückenmarksgewebe. Immunitätsf Exp Therapie 1925 42 : 217 83.
3. Polman CH, O'Connor PW, Havrdova E et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006 9 : 899 910.
4. Kappos L, Antel J, Comi G et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006 355 : 1124 40.
5. Matloubian M, Lo CG, Cinamon G et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004 427 : 355 60.
6. Islam T, Gauderman WJ, Cozen W, Hamilton AS, Burnett ME, Mack TM. Differential twin concordance for multiple sclerosis by latitude of birthplace. Ann Neurol 2006 60 : 56 64.
7. Moller E, Bohme J, Valugerdi MA, Ridderstad A, Olerup O. Speculations on mechanisms of HLA associations with autoimmune diseases and the specificity of 'autoreactive' T lymphocytes. Immunol Rev 1990 118 : 5 19.
8. Jersild C, Svejgaard A, Fog T. HLA antigens and multiple sclerosis. Lancet 1972 1 : 1240 1.
9. Barcellos LF, Oksenberg JR, Green AJ et al. Genetic basis for clinical expression in multiple sclerosis. Brain 2002 125 : 150 8.
10. Barcellos LF, Oksenberg JR, Begovich AB et al. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet 2003 72 : 710 6.
11. Ploski R, Ek J, Thorsby E, Sollid LM. On the HLA-DQ (alpha 1*0501, beta 1*0201)-associated susceptibility in celiac disease: a possible gene dosage effect of DQB1*0201. Tissue Antigens 1993 41 : 173 7.
12. Vader W, Stepniak D, Kooy Y et al. The HLA-DQ2 gene dose effect in celiac disease is directly related to the magnitude and breadth of gluten-specific T cell responses. Proc Natl Acad Sci U S A 2003 100 : 12390 5.
13. Spurkland A, Celius EG, Knutsen I, Beiske A, Thorsby E, Vartdal F. The HLA-DQ (alpha 1*0102, beta 1*0602) heterodimer may confer susceptibility to multiple sclerosis in the absence of the HLA-DR (alpha 1*01, beta 1*1501) heterodimer. Tissue Antigens 1997 50 : 15 22.
14. Caballero A, Alves-Leon S, Papais-Alvarenga R, Fernandez O, Navarro G, Alonso A. DQB1*0602 confers genetic susceptibility to multiple sclerosis in Afro-Brazilians. Tissue Antigens 1999 54 : 524 6.
15. Oksenberg JR, Barcellos LF, Cree BA et al. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet 2004 74 : 160 7.
16. Olsson T, Jagodic M, Piehl F, Wallstrom E. Genetics of autoimmune neuroinflammation. Curr Opin Immunol 2006 18 : 643 9.
17. Barcellos LF, Kamdar BB, Ramsay PP et al. Clustering of autoimmune diseases in families with a high-risk for multiple sclerosis: a descriptive study. Lancet Neurol 2006 5 : 924 31.
18. Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005 202 : 473 7.
19. Cabre P, Signate A, Olindo S et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies. Brain 2005 128 : 2899 910.
20. Ebers GC, Sadovnick AD, Risch NJ. A genetic basis for familial aggregation in multiple sclerosis. Canadian Collaborative Study Group. Nature 1995 377 : 150 1.
21. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann Neurol 2006 59 : 499 503.
22. Bray PF, Bloomer LC, Salmon VC, Bagley MH, Larsen PD. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch Neurol 1983 40 : 406 8.
23. Pohl D, Krone B, Rostasy K et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 2006 67 : 2063 5.
24. DeLorenze GN, Munger KL, Lennette ET, Orentreich N, Vogelman JH, Ascherio A. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch Neurol 2006 63 : 839 44.
25. Lang HL, Jacobsen H, Ikemizu S et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat Immunol 2002 3 : 940 3.
26. Holmoy T, Kvale EO, Vartdal F. Cerebrospinal fluid CD4+ T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. J Neurovirol 2004 10 : 278 83.
27. Swank RL, Lerstad O, Strøm A, Backer J. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. N Engl J Med 1952 246 : 722 8.
28. McLeod JG, Hammond SR, Hallpike JF. Epidemiology of multiple sclerosis in Australia. With NSW and SA survey results. Med J Aust 1994 160 : 117 22.
29. van dM I, Ponsonby AL, Dwyer T et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. BMJ 2003 327 : 316.
30. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006 296 : 2832 8.
31. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science 1983 221 : 1181 3.
32. Tsoukas CD, Provvedini DM, Manolagas SC. 1,25-dihydroxyvitamin D3: a novel immunoregulatory hormone. Science 1984 224 : 1438 40.
33. Cantorna MT, Hayes CE, Deluca HF. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci U S A 1996 93 : 7861 4.
34. Muthian G, Raikwar HP, Rajasingh J, Bright JJ. 1,25 Dihydroxyvitamin-D3 modulates JAK-STAT pathway in IL-12/IFNgamma axis leading to Th1 response in experimental allergic encephalomyelitis. J Neurosci Res 2006 83 : 1299 309.
35. Spach KM, Nashold FE, Dittel BN, Hayes CE. IL-10 signaling is essential for 1,25-dihydroxyvitamin D3-mediated inhibition of experimental autoimmune encephalomyelitis. J Immunol 2006 177 : 6030 7.
36. Mahon BD, Gordon SA, Cruz J, Cosman F, Cantorna MT. Cytokine profile in patients with multiple sclerosis following vitamin D supplementation. J Neuroimmunol 2003 134 : 128 32.
37. Raine CS, Scheinberg LC. On the immunopathology of plaque development and repair in multiple sclerosis. J Neuroimmunol 1988 20 : 189 201.
38. Bö L, Geurts JJG, Mörk SJ, van der Valk P. Grey matter pathology in multiple sclerosis. Acta Neurol Scand 2006 113 (s183 48 50.
39. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol 1992 140 : 691 707.
40. Barnett MH, Prineas JW. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004 55 : 458 68.
41. Moalem G, Leibowitz-Amit R, Yoles E, Mor F, Cohen IR, Schwartz M. Autoimmune T cells protect neurons from secondary degeneration after central nervous system axotomy. Nat Med 1999 5 : 49 55.
42. Kerschensteiner M, Gallmeier E, Behrens L et al. Activated human T cells, B cells, and monocytes produce brain-derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med 1999 189 : 865 70.
43. Lucchinetti C, Bruck W, Parisi J, Scheithauer B, Rodriguez M, Lassmann H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000 47 : 707 17.
44. Keegan M, Konig F, McClelland R et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet 2005 366 : 579 82.
45. Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol 2005 23 : 683 747.
46. Ota K, Matsui M, Milford EL, Mackin GA, Weiner HL, Hafler DA. T-cell recognition of an immunodominant myelin basic protein epitope in multiple sclerosis. Nature 1990 346 : 183 7.
47. Wucherpfennig KW, Zhang J, Witek C et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994 152 : 5581 92.
48. Goebels N, Hofstetter H, Schmidt S, Brunner C, Wekerle H, Hohlfeld R. Repertoire dynamics of autoreactive T cells in multiple sclerosis patients and healthy subjects: epitope spreading versus clonal persistence. Brain 2000 123 : 508 18.
49. Madsen LS, Andersson EC, Jansson L et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 1999 23 : 343 7.
50. Burns J, Rosenzweig A, Zweiman B, Lisak RP. Isolation of myelin basic protein-reactive T-cell lines from normal human blood. Cell Immunol 1983 81 : 435 40.
51. Jingwu Z, Medaer R, Hashim GA, Chin Y, Berg-Loonen E, Raus JC. Myelin basic protein-specific T lymphocytes in multiple sclerosis and controls: precursor frequency, fine specificity, and cytotoxicity. Ann Neurol 1992 32 : 330 8.
52. Kerlero dR, Milo R, Lees MB, Burger D, Bernard CC, Ben Nun A. Reactivity to myelin antigens in multiple sclerosis. Peripheral blood lymphocytes respond predominantly to myelin oligodendrocyte glycoprotein. J Clin Invest 1993 92 : 2602 8.
53. Holmoy T, Vandvik B, Vartdal F. T cells from multiple sclerosis patients recognize immunoglobulin G from cerebrospinal fluid. Mult Scler 2003 9 : 228 34.
54. Olsson T, Zhi WW, Hojeberg B et al. Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-gamma. J Clin Invest 1990 86 : 981 5.
55. Soderstrom M, Link H, Sun JB et al. T cells recognizing multiple peptides of myelin basic protein are found in blood and enriched in cerebrospinal fluid in optic neuritis and multiple sclerosis. Scand J Immunol 1993 37 : 355 68.
56. Tejada-Simon MV, Zang YC, Yang D et al. Aberrant T cell responses to myelin antigens during clinical exacerbation in patients with multiple sclerosis. Int Immunol 2000 12 : 1641 50.
57. Allegretta M, Nicklas JA, Sriram S, Albertini RJ. T cells responsive to myelin basic protein in patients with multiple sclerosis. Science 1990 247 : 718 21.
58. Bielekova B, Goodwin B, Richert N et al. Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000 6 : 1167 75.
59. Gay FW, Drye TJ, Dick GW, Esiri MM. The application of multifactorial cluster analysis in the staging of plaques in early multiple sclerosis. Identification and characterization of the primary demyelinating lesion. Brain 1997 120 : 1461 83.
60. Babbe H, Roers A, Waisman A et al. Clonal expansions of CD8(+) T cells dominate the T cell infiltrate in active multiple sclerosis lesions as shown by micromanipulation and single cell polymerase chain reaction. J Exp Med 2000 192 : 393 404.
61. Skulina C, Schmidt S, Dornmair K et al. Multiple sclerosis: brain-infiltrating CD8+ T cells persist as clonal expansions in the cerebrospinal fluid and blood. Proc Natl Acad Sci U S A 2004 10 : 2428 33.
62. Sun D, Whitaker JN, Huang Z et al. Myelin antigen-specific CD8+ T cells are encephalitogenic and produce severe disease in C57BL/6 mice. J Immunol 2001 166 : 7579 87.
63. Huseby ES, Liggitt D, Brabb T, Schnabel B, Ohlen C, Goverman J. A pathogenic role for myelin-specific CD8(+) T cells in a model for multiple sclerosis. J Exp Med 2001 194 : 669 76.
64. Banki K, Colombo E, Sia F et al. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J Exp Med 1994 180 : 1649 63.
65. Zang YC, Li S, Rivera VM et al. Increased CD8+ cytotoxic T cell responses to myelin basic protein in multiple sclerosis. J Immunol 2004 1725 : 120 7.
66. Condie RM, Kelly JT, Campbell B, Good RA. Prevention of experimental encephalomyelitis by prior injections of homologous spinal cord. Fed Proc 1957 16 : 24.
67. Svet-Moldavskaya IA, Svet-Moldavsky GJ. Acquired resistance to experimental allergic encephalomyelitis. Nature 1958 181 : 1536 7.
68. Fontoura P, Garren H, Steinman L. Antigen-specific therapies in multiple sclerosis: going beyond proteins and peptides. Int Rev Immunol 2005 24 : 415 46.
69. Sospedra M, Martin R. Antigen-specific therapies in multiple sclerosis. Int Rev Immunol 2005b 24 : 393 413.
70. Warren KG, Catz I, Ferenczi LZ, Krantz MJ. Intravenous synthetic peptide MBP8298 delayed disease progression in an HLA class II-defined cohort of patients with progressive multiple sclerosis: results of a 24-month double-blind placebo-controlled clinical trial and 5 years of follow-up treatment. Eur J Neurol 2006 13 : 887 95.
71. Kappos L, Comi G, Panitch H et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 2000 6 : 1176 82.
72. Ben-Nun A, Wekerle H, Cohen IR. Vaccination against autoimmune encephalomyelitis with T-lymphocyte line cells reactive against myelin basic protein. Nature 1981 292 : 60 1.
73. Lider O, Reshef T, Beraud E, Ben Nun A, Cohen IR. Anti-idiotypic network induced by T cell vaccination against experimental autoimmune encephalomyelitis. Science 1988 239 : 181 3.
74. Zhang J, Medaer R, Stinissen P, Hafler D, Raus J. MHC-restricted depletion of human myelin basic protein-reactive T cells by T cell vaccination. Science 1993 261 : 1451 4.
75. Lohse AW, Mor F, Karin N, Cohen IR. Control of experimental autoimmune encephalomyelitis by T cells responding to activated T cells. Science 1989 244 : 820 2.
76. Quintana FJ, Cohen IR. Anti-ergotypic immunoregulation. Scand J Immunol 2006 64 : 205 10.
77. Chen G, Li N, Zang YC et al. Vaccination with selected synovial T cells in rheumatoid arthritis. Arthritis Rheum 2007 56 : 453 63.
78. Panitch H, Francis G, Oral Myelin Study Group. Clinical results of a phase III trial in of oral myelin in relapsing remitting multiple sclerosis. Ann Neurol 1997 42 : 467.
79. Weiner HL, Mackin GA, Matsui M et al. Double-blind pilot trial of oral tolerization with myelin antigens in multiple sclerosis. Science 1993 259 : 1321 4.
80. Coles AJ, Cox A, Le PE et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006 253 : 98 108.
81. van Noort JM, van Sechel AC, Bajramovic JJ et al. The small heat-shock protein alpha B-crystallin as candidate autoantigen in multiple sclerosis [see comments]. Nature 1995 375 : 798 801.
82. Bajramovic JJ, Plomp AC, Goes A et al. Presentation of alpha B-crystallin to T cells in active multiple sclerosis lesions: an early event following inflammatory demyelination. J Immunol 2000 164 : 4359 66.
83. Bajramovic JJ, Bsibsi M, Geutskens SB et al. Differential expression of stress proteins in human adult astrocytes in response to cytokines. J Neuroimmunol 2000 106 : 14 22.
84. van Noort JM, Bajramovic JJ, Plomp AC, van Stipdonk MJ. Mistaken self, a novel model that links microbial infections with myelin-directed autoimmunity in multiple sclerosis. J Neuroimmunol 2000 105 : 46 57.
85. van Sechel AC, Bajramovic JJ, van Stipdonk MJ, Persoon-Deen C, Geutskens SB, van Noort JM. EBV-induced expression and HLA-DR-restricted presentation by human B cells of alpha B-crystallin, a candidate autoantigen in multiple sclerosis. J Immunol 1999 162 : 129 35.
86. Wang C, Chou YK, Rich CM et al. AlphaB-crystallin-reactive T cells from knockout mice are not encephalitogenic. J Neuroimmunol 2006 176 : 51 62.
87. Verbeek R, van Dongen H, Wawrousek EF, Amor S, van Noort JM. Induction of EAE by T cells specific for alpha B-crystallin depends on prior viral infection in the CNS. Int Immunol 2007 19 : 277 85.
88. Weiss S, Bogen B. MHC class II-restricted presentation of intracellular antigen. Cell 1991 64 : 767 76.
89. Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA Jr. Sequence analysis of peptides bound to MHC class II molecules. Nature 1991 353 : 622 7.
90. Bogen B, Jorgensen T, Hannestad K. T helper cell recognition of idiotopes on lambda 2 light chains of M315 and T952: evidence for dependence on somatic mutations in the third hypervariable region. Eur J Immunol 1985 15 : 278 81.
91. Mendlovic S, Brocke S, Shoenfeld Y et al. Induction of a systemic lupus erythematosus-like disease in mice by a common human anti-DNA idiotype. Proc Natl Acad Sci U S A 1988 85 : 2260 4.
92. Munthe LA, Corthay A, Os A, Zangani M, Bogen B. Systemic autoimmune disease caused by autoreactive B cells that receive chronic help from Ig V region-specific T cells. J Immunol 2005 175 : 2391 400.
93. Laterre EC, Callewaert A, Heremans JF, Sfaello Z. Electrophoretic morphology of gamma globulins in cerebrospinal fluid of multiple sclerosis and other diseases of the nervous system. Neurology 1970 20 : 982 90.
94. Vartdal F, Vandvik B, Norrby E. Viral and bacterial antibody responses in multiple sclerosis. Ann Neurol 1980 8 : 248 55.
95. Vartdal F, Vandvik B. Multiple sclerosis: subclasses of intrathecally synthesized IgG and measles and varicella zoster virus IgG antibodies. Clin Exp Immunol 1983 54 : 641 7.
96. Qin Y, Duquette P, Zhang Y, Talbot P, Poole R, Antel J. Clonal expansion and somatic hypermutation of V(H) genes of B cells from cerebrospinal fluid in multiple sclerosis. J Clin Invest 1998 102 : 1045 50.
97. Smith-Jensen T, Burgoon MP, Anthony J, Kraus H, Gilden DH, Owens GP. Comparison of immunoglobulin G heavy-chain sequences in MS and SSPE brains reveals an antigen-driven response. Neurology 2000 54 : 1227 32.
98. Holmoy T, Fredriksen AB, Thompson KM, Hestvik AL, Bogen B, Vartdal F. Cerebrospinal fluid T cell clones from patients with multiple sclerosis: recognition of idiotopes on monoclonal IgG secreted by autologous cerebrospinal fluid B cells. Eur J Immunol 2005 35 : 1786 94.
99. Niino M, Bodner C, Simard ML et al. Natalizumab effects on immune cell responses in multiple sclerosis. Ann Neurol 2006 59 : 748 54.
100. De Jager PL, Hafler DA. New therapeutic approaches for multiple sclerosis. Annu Rev Med 2007 58 : 417 32.